Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vanguard Mega Cap Growth ETF (MGK) vs Morgan Stanley (MS) Price & Performance

Vanguard Mega Cap Growth ETFTrade
Morgan StanleyTrade

Price performance (Past 24H)

Key statistics

Vanguard Mega Cap Growth ETF vs Morgan Stanley — how do they compare? Vanguard Mega Cap Growth ETF trades at $94.02 (market cap $33.70B), while Morgan Stanley trades at $187.81 (market cap $297.95B). The key difference: Morgan Stanley is far larger — about 8.8× Vanguard Mega Cap Growth ETF's market cap, and Morgan Stanley pays a 2.42% dividend while Vanguard Mega Cap Growth ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Mega Cap Growth ETF for 45 Days and Morgan Stanley for 93 Days on average.

MGKMS
Market Cap
$33.70B$297.95B
Volume
1,290,4065,030,247
Sector
Broad Market / FactorFinancials
52-Week High
$95.11$228.42
52-Week Low
$70.70$151.86
Typical Hold Time
45 Days93 Days
Enterprise Value
—$663.67B
Dividend Yield
—2.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vanguard Mega Cap Growth ETF

MGK trades at $94.92, down 0.2% on the day, with a bullish technical signal from moving averages but bearish momentum from oscillators. The ETF focuses on large-cap US growth stocks with heavy technology concentration, offering low 0.05% expense ratio exposure to companies like Nvidia, Apple, and Microsoft. Recent articles highlight its strong five-year performance and appeal for long-term growth investors seeking mega-cap stability.

MGK presents a compelling growth ETF option with concentrated mega-cap exposure, though its tech-heavy composition increases sector-specific risk. The fund's low costs and historical outperformance make it suitable for investors with higher risk tolerance, while current technical indicators suggest potential near-term consolidation after recent gains.

Morgan Stanley

Morgan Stanley (MS) trades at $187.41, down 1.86% on the day, with a bearish technical signal but strong fundamentals including a P/E of 15.32 and net income margin of 27.59%. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is robust, rising from $50.2B in 2022 to $66.0B in 2025, and the company highlights growth opportunities in wealth management and AI financing.

The outlook is supported by a bullish analyst consensus with a $229.25 price target, though risks include volatile cash flows and rising debt-to-asset ratios. Near-term price action is testing support near $184, with investor sentiment mixed amid fading capital markets momentum but positive long-term growth narratives.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MGK
100% Buy0% Sell
Avg holding period · 45 Days
MS
100% Buy0% Sell
Avg holding period · 93 Days

Top news

Latest headlines on both assets

About Vanguard Mega Cap Growth ETF

MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.

Read more on MGK →

About Morgan Stanley

Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.

Read more on MS →